A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Terminated · Phase 1, Phase 2 · NCT03215030
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $903,767
- U.S. investigators named
- 17
- Sites paid
- 17
- Planned or actual enrollment
- 272
About the trial
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Tested
- Modakafusp alfa (drug), Dexamethasone (drug)
- Dates
- Started 2017-10-04; completion 2024-11-07
- Results posted
- Yes
The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will rec…
From ClinicalTrials.gov, last updated 2026-01-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $903,767 in research payments for this study in 2025 (39 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Patrick M. Travis, M.D. General Practice · Springdale, AR
- Lasika C. Seneviratne, M.D. Hematology & Oncology · Los Angeles, CA
- Terri L. Parker, M.D. Hematology & Oncology · New Haven, CT
- Jonathan L. Kaufman, M.D. Medical Oncology · Atlanta, GA
- Patrick A. Hagen, M.D., M.P.H Hematology & Oncology · Maywood, IL
- Omar Nadeem, M.D. Hematology · Boston, MA
- Christian B. Gocke, M.D., PH.D. Medical Oncology · Baltimore, MD
- Shebli Atrash, MD Hematology & Oncology · Charlotte, NC
- Sarah A. Holstein, MD Hematology · Omaha, NE
- Noa Biran, M.D. Medical Oncology · Hackensack, NJ
- Nishi Shah, MBBS Hematology & Oncology · Bronx, NY
- Srinivas S. Devarakonda, MD Hematology · Columbus, OH
- Yubin Kang, M.D. Hematology · Oklahoma City, OK
- John M. Kirkwood, MD Specialist · Pittsburgh, PA
- Dan T. Vogl, MD Hematology · Philadelphia, PA
- Hector A. Velez Cortes, MD Hematology & Oncology · Ponce, PR
- David M. Gill Medical Oncology · Murray, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Atrium Health Union, NC $262,840
- Hospital of Univ of Pennsylvania, PA $156,157
- Unehealth $151,622
- Biomedical Research Alliance of New York LLC $64,546
- Emory University Hospital, GA $56,091
- Duke Regional Hospital, NC $51,913
- Arthur G James Cancer Hospital $40,578
- Johns Hopkins University $38,676
- $22,322
- Highlands Oncology Group $20,177
- Hackensack University Medical Center, NJ $16,995
- Intermountain Medical Center, UT $7,798
- Yale University $3,576
- Dana-Farber Cancer Institute $2,563
- Loyola University Medical Center, IL $2,387
- Los Angeles Hematology Oncology Medical Group $2,104
- Advance Medical Research LLC $1,733
- University of Pittsburgh Cancer Institute Cancer Services $1,689
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.